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INTERPLAY BETWEEN KERATIN AND VIMENTIN EXPRESSION IN ORAL
CANCER
By Mary Catherine McGinn, M.S.
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Previous research in our laboratory found that inhibiting expression of vimentin, a
marker of epithelial-to mesenchymal transition, inhibited cell growth and motility in vitro
and in vivo. Tumors derived from vimentin knockdown cells showed features of epithelial
redifferentiation and increased expression of differentiation-specific keratins. It is
unknown what causes re-expression of keratins when vimentin is inhibited. Although,
canonical Wnt signaling may activate NF-?B and repress of keratin and/or induce vimentin
expression through ß-catenin. We hypothesize that ownregulation of differentiationspecific keratins contributes to tumor progression, mediated directly or indirectly by
xiv

xv
expression of vimentin. Vimentin- negative HN4 cells were transfected with plasmids
encoding wild-type, PKCe-phosphomimetic, or unphosphorylatable versions of vimentin.
Expression of vimentin was confirmed by western blot and immunofluorescence. Effects
on cell growth and motility were determined using MTT, cell proliferation, and woundclosure assays. These results indicate that mutation of vimentin PKCe-phosphorylation
sites cause changes in proliferation and filament assembly. Treatment of cells with an NF?B inhibitor or 5-Aza-C, which allows re-expression of the Wnt inhibitor DKK3, led to a
decrease in proliferation. These results suggest that inhibiting Wnt signaling removes the
inhibition on GSK-3ß and prevents activation of NF-?B, which decreases proliferation.

Introduction
Cancer and Tumor Growth
Cancer cells develop due to changes in normal controls that regulate cell
proliferation and homeostasis. There are genetic regulatory systems that maintain a balance
between cell birth and death through growth signals, growth inhibitory signals, and death
signals (Lodish, 2004). Normal control of cell division is maintained by extracellular
growth factors, and errors in generating, regulating, or recognizing these growth factors
can result in cancer (Lehninger, Nelson, & Cox, 2005). Six hallmarks have been generated
that classify changes leading to cancer cell growth. These six characteristics are “self
sufficiency in growth signals, insensitivity to growth- inhibitory (antigrowth) signals,
evasion of programmed cell death (apoptosis), limitless replicative potential, sustained
angiogenesis, and tissue invasion and metastasis” (Hanahan & Weinberg, 2000). Most
human tumors possess these six traits. Normal cells require growth signals before
transitioning from the quiescent to proliferative state, but tumor cells are not, in many
cases, dependent on these growth signals, as they frequently create their own. Many of the
cell surface receptors that induce growth signals are deregulated during tumorigenesis.
Additionally, normal tissues have antiproliferative signals to maintain homeostasis, and
these operate through two mechanisms. One mechanism forces cells to exit the cell cycle
and into a quiescent state. These cells may reenter the cell cycle in the presence of
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appropriate extracellular signals. The other mechanism prevents the cell from ever
proliferating again, and it enters a postmitotic state. Tumor cells have acquired
mechanisms to bypass this terminal differentiation (Hanahan & Weinberg, 2000).
Mutations in two classes of genes are frequently involved in cancer. These genes
are proto-oncogenes and tumor suppressor genes. Proto-oncogenes are normally involved
in cell growth, but mutations can change them into oncogenes causing excessive growth
(Lodish, 2004). These oncogenes can be activated by genetic or epigenetic factors. Genetic
changes occur due to mutation, deletion, amplification, or translocation. A single
mutational event can cause the proto-oncogene to contribute to cancer. Epigenetic factors
are a result of heritable changes in the gene that operate outside changes in the DNA itself.
This could be due to methylation or histone modification and may also influence the
expression of oncogenes or tumor suppressor genes (Palmieri et al., 2009). On the other
hand, tumor suppressor genes normally prevent growth. When mutations occur, these
genes are inactivated which enables cells to proliferate with unregulated and self- sufficient
growth. In order for tumor suppressor genes to contribute to cancer, both alleles must be
mutated, so this requires two mutational events (Lodish, 2004). The presence of
environmental carcinogens can cause changes in these tumor suppressor genes and protooncogenes, which results in malignant transformation of the cells. Telomerase, which is
involved in immortalization, shows reactivation in approximately 90% of head and neck
squamous cell carcinomas. These initial changes cause further genetic instability and lead
to characteristics of malignant cells (Stadler, Patel, Couch, & Hayes, 2008).
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Cancer is the result of phenotypic and genetic changes that ultimately result in
aggressive behavior. A normal cell gets mutated which causes increased proliferation.
Further mutations lead to the formation of a benign neoplasm or “new growth.” The initial
neoplasm usually appears in an organ as a solid mass. With increasing chromosomal
changes, a carcinoma is formed (Muir & Anderson, 1985). A carcinoma is a malignant
tumor originating from the epithelia and accounts for over ninety percent of malignant
tumors. Tumors are very common, but they usually do not pose any threat to the host
because they are small and localized. These tumors are termed benign. The cellular
makeup of benign tumors is very similar to normal cells, and their cell-adhesion molecules
keep the tumor contained to the original site (Lodish, 2004). Benign tumors are generally
encapsulated and slow growing. From the microscopic level, they are usually well
differentiated and uniform throughout (Muir & Anderson, 1985). However, a malignant
tumor contains cells that grow rapidly. This type of tumor is also known as cancer. Their
ability to invade and spread to distant areas differentiates malignant tumors from benign
tumors (Lodish, 2004).

Metastasis
Metastasis is the process where primary tumor cells migrate to a different location
and form secondary tumors. The tissues most likely to be attacked are those that create
growth factors and generate new vasculature. These tissues include bone, blood vessels,
and the liver. The process of metastasis can be divided into several steps. First, the
individual tumor cells separate from the primary tumor. These malignant cells must
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permeate the basement membrane, get through the extracellular matrix, and intravasate
into the blood or lymphatic vessels (Howell & Grandis, 2005). Breaking down the
basement membrane enables the tumor cells to enter the blood, but only a small percentage
survive to form a secondary tumor (Lodish, 2004). From this stage, the cells can migrate to
different sites. Before a metastatic tumor is formed, the cells must invade the target organ
(Howell & Grandis, 2005). The process requires communication with tumor cells, stromal
cells, extracellular matrix, and vasculature mediated by growth factors, cytokines, and
enzymes (Miyazaki et al., 2006). Malignant tumors have atypical structure, and they are
usually less differentiated. The cells have a loss of polarity and tend to have abnormal
mitotic figures (Muir & Anderson, 1985).
Several proteins are involved in making cells capable of invasion and metastasis.
Two classes are cell-cell adhesion molecules and integrins. Cell adhesion molecules are
found on all cells and provide a connection between the extracellular matrix and
cytoskeleton. These molecules are involved in communication between the interior and
exterior of the cell and processes such as growth, proliferation, and migration. Integrins are
adhesion receptors that are responsible for adhesion to the adjacent matrix (Lyons & Jones,
2007). Cadherins are a part of the intracellular adhesions in normal cells (Kramer, Shen, &
Zhou, 2005). As the cells migrate through the extracellular matrix, they change these
intracellular adhesions. E-cadherin, which is expressed in epithelial cells, is frequently
altered in cancers. This is done by inactivating E-cadherin or ß-catenin genes, repressing
the transcriptional activity, or degrading the cadherin extracellular domain. Experiments
show that the loss of E-cadherin function is a factor in invasion and metastasis by epithelial
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cancers. Carcinomas can also increase their invasion potential by altering integrin
expression (Hanahan & Weinberg, 2000). The integrin receptors interacting with the
extracellular matrix ligands, in addition to changes in the cadherins, result in cytoskeleton
remodeling by Rho family members (Kramer et al., 2005). Extracellular proteases also
play a role in invasion and metastasis. Protease gene expression is increased, protease
inhibitors are decreased, and zymogen forms of proteases are activated (Hanahan &
Weinberg, 2000).

Head and Neck Cancer
Cancer causes approximately one-fifth of the deaths annually in the United States,
with 100 to 350 deaths out of every 100,000 people worldwide (Lodish, 2004). Squamous
cell carcinoma is the most prevalent form of head and neck cancer. In most cases, cells
derived from these tumors are anchorage dependent and usually do not grow in semi- solid
cultures. This emphasizes the role of cellular and extracellular matrix interactions (Ziober,
Silverman, & Kramer, 2001). Head and neck squamous cell carcinoma (HNSCC) is also
the fifth most prevalent form of cancer in the world (Mandal et al., 2008). It involves
cancer of the oral cavity, pharynx, and larynx. Overall, only fifty percent of patients
diagnosed with head and neck cancer will survive for five years. This survival rate is lower
for patients presenting with more advanced cancer and around 4% for patients with stage
IV hypopharyngeal lesions (Miyazaki et al., 2006). However, there is an eighty-two
percent five-year survival rate for patients with localized oral cancer (Oral cancer.2009).
The overall low survival rate is due to cancer reoccurrence and local invasion.
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Additionally, head and neck cancer is commonly in an advanced stage when it is
recognized and treated (Ziober et al., 2001). This form of cancer frequently spreads to the
lymph nodes of the neck due to the invasive nature of the cells and the amount of
lymphatic drainage from the oral cavity (Kramer et al., 2005). In 2009, it was estimated
that there would be 35,720 new cases and 7,600 deaths from oral cancer in the United
States (Oral cancer.2009).
There are several risk factors for head and neck cancer, the most well known of
which is tobacco use, and HNSCC was one of the first tumor types found to have P53
mutation due to tobacco (Stadler et al., 2008). Men are more likely to have oral cancer than
women, because traditionally men abuse alcohol and tobacco for longer periods of time.
Oral cancer is more common after age thirty- five, with half the patients diagnosed over age
sixty-eight. Of the patients diagnosed with oral cancer, 90% use tobacco, and the
likelihood of developing cancer increases with the amount and duration of time the tobacco
is used. Additionally, 75 to 80% of patients with oral cancer drink alcohol regularly (Oral
cancer.2009).
Surgery, radiation therapy, chemotherapy, and newly targeted therapy are the
current treatment options for patients with HNSCC (Oral cancer.2009). Surgery is the
primary form of treatment, but this can have a large effect on the patient’s physical
appearance (Yeudall et al., 2005). Radiation therapy is frequently used for small cancers,
but can be combined with other treatment options for larger cancers. Post-operative
radiotherapy is also used to kill remaining cells that have not been removed surgically
(Oral cancer.2009). Unfortunately, HNSCC does not respond well to radiation or
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chemotherapy treatments (Yeudall et al., 2005). One targeted therapy used for HNSCC
involves the epidermal growth factor receptor, which is frequently upregulated in this
cancer and allows the cells to have resistance against radiation and chemotherapy (Oral
cancer.2009). Immunotherapy is also emerging as a form of treatment for HNSCC
(Rapidis & Wolf, 2009). Since an effective treatment does not exist, early detection and
prevention have a large role in preventing death as a result of HNSCC (Yeudall et al.,
2005).

Intermediate Filaments
Intermediate filaments are a class of filaments of around 10 nm in diameter making
them smaller than microtubules and larger than microfilaments. Microtubules,
microfilaments, and intermediate filaments are the main cytoskeletal components in
mammalian cells. Intermediate filaments are a part of most differentiated cells and are
present in the nucleus and cytoplasm. They are dynamic structures that are constantly
reassembling and interacting with the cytoskeleton and cellular organelles (Parry &
Steinert, 1995). There are around seventy genes in the human genome encoding different
intermediate filaments, and they have been categorized into different types. Type I consists
of acidic keratins, and all other keratins (neural and basic) are type II. Keratins are the most
numerous and complex intermediate filaments. They cannot form polymers with other
intermediate filaments. Keratins are only able to form heteropolymers, because both type I
and type II keratins are required for assembly. Desmin, vimentin, periphin, and GFAP
(glial filament acidic protein) are all type III intermediate filament proteins. Type III
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proteins can form homopolymers and heteropolymers with other proteins in the type III
family. Type IV intermediate filament proteins are associated with nerve cells and affect
the growth of axons. This type includes a- internexin and neurofilament proteins NF-L, NFM, and NF-H. These types of intermediate filament proteins are further grouped according
to their sequence homology. Group one consists of the keratins. Type III and IV make up
group two, while the third group contains the lamins. The primary function for
intermediate filament proteins is maintaining the cell and tissue structure. The organization
of organelles and proteins inside the cell is also affected by intermediate filaments.
Although there is great variety between the different intermediate filaments, they have the
same basic structure. There is a central a-helical domain that is surrounded by a nonhelical N-terminal (“head”) domain and a C-terminal (“tail”) domain. The “head” and
“tail” domains vary in size and primary amino acid sequence among the different types of
intermediate filaments. However, the central domain remains the same throughout the
types (Minin & Moldaver, 2008).

Vimentin
Vimentin is a 54 kDa type III intermediate filament that is found in fibroblasts,
lymphocytes, endothelial cells, and most mesenchymal tissues. It is also present in a lot of
cells during early development. Vimentin filaments combine to create a cytoskeletal
network originating at the nucleus and spreading to the plasma membrane throughout the
cytoplasm (Paramio, 2006). Vimentin has been shown to move towards the cell surface
and the nucleus. It also has the ability to move in multiple directions along the microtubule
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due to the motor proteins kinesin and dynein (Minin & Moldaver, 2008). Vimentin
interacts with kinesin through a vimentin-associated protein. This interaction causes
vimentin to move towards the microtubule plus-ends and the cell surface (Gyoeva &
Gelfand, 1991). Vimentin also associates with dynein and dynactin, which are responsible
for vimentin moving to the microtubule minus-ends and the cell nucleus (Eriksson et al.,
2004). Vimentin expression has been shown in breast cancer cell lines, and there are links
between vimentin levels and invasive cervical cancer. The presence of vimentin has been
reported in several human epithelial tumors including renal, thyroid, ovarian, and
pulmonary carcinomas (Gilles et al., 1996). Vimentin has also been found overexpressed in
invasive prostate cancer cells (Singh et al., 2003).

Vimentin Gene Expression
Several transcriptional regulatory elements have been discovered that affect
vimentin gene expression. The human vimentin gene has multiple transcription factor
binding sites. These sites include “a consensus TATA box, a GC box indispensable for
expression and interacting with Sp/XKLF factors, a PEA3 binding site, a NF-?B site, a
repressor site, a tandem AP1 binding site, and an anti-silencer element” (Zhou, Kahns, &
Nielsen, 2009).

Keratin
Keratins form type I and type II intermediate filaments, and they are found in
almost all epithelial cells. They are involved in physiological functions such as maintaining

10
the cell shape and assembling cell-substrate and cell-cell adhesion sites (Ghosh et al.,
2002). Keratins also help protect epithelial cells from stresses that could cause the cells to
rupture. Their molecular weights range between 40 to 70 kDa (Gu & Coulombe, 2007),
with K13, K14, and K15 around 50 kDa. The gene expression of keratins is
developmentally regulated, thus different stages of development are characterized by
different keratins. All keratin intermediate filaments include a type I and a type II filament.
Additionally, K13, K14, and K15 are all expressed in non-keratinizing stratified squamous
epithelia (Chu & Weiss, 2002).

Epithelial to Mesenchymal Transition
The process where epithelial cells become mobile by detaching from their normal
junctions and start migrating is known as the epithelial to mesenchymal transition (EMT).
EMT is considered a marker of tumor progression indicating invasive and metastatic
carcinomas (Voulgari & Pintzas, 2009). Epithelial cells are characterized for being
polarized and maintaining tight junction with their neighboring cells, which prevents
movement. These cells are normally rich in keratin intermediate filaments, whereas
mesenchymal cells do not possess the well-defined intracellular junctions and are motile
(Guarino, 2007). These cells typically have a spindle- like structure and exhibit front-toback polarity, and vimentin is the major intermediate filament present in mesenchymal
cells (Hollier, Evans, & Mani, 2009). EMT occurs during many developmental processes
including gastrulation, as well as playing a large part in cancer progression. Several steps
have defined the process. First, various signaling pathways are modified which determine a
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group of cells that will undergo EMT. Next, the intracellular adhesions maintained by
cadherins are lost along with the polarity markers. The cell has changes in the cytoskeleton
that promote cell delamination, and ultimately, the basement membrane is disassembled
(Levayer & Lecuit, 2008). For this reason, EMT is considered an important step leading to
metastasis. At the molecular level, EMT is represented by a decrease in E-cadherin and
cytokeratins with an increase in the mesenchymal marker vimentin (Lester, Jo, Montel,
Takimoto, & Gonias, 2007).

Regulation of Vimentin
The stability, structure, and assembly of intermediate filament polymers can be
regulated by phosphorylation. Phosphorylation of intermediate filaments can also mediate
interactions with other intermediate filament associated proteins and affect some tissuespecific structural roles (Liao & Omary, 1996). One study showed that the assemblydisassembly balance of vimentin by phosphorylation could regulate activation of RhoAbinding kinase a (Goto et al., 1998). A high constitutive protein phosphatase activity is
paired with intermediate filaments, which implies these proteins have a larger phosphate
turnover (Eriksson et al., 1992). With multiple high phosphorylation turnover sites on
vimentin, PKA and PKC appear as the most likely regulatory kinases. By increasing
phosphorylation at the sites mediated by PKA, there is disassembly into tetrameric
subunits. The balance between vimentin polymers and depolymerized subunits and the
turnover is regulated by kinase-phosphatase equilibrium. This is regulated by reversible
phosphoryla tion at sites in the N-terminal part of vimentin. However, if Ser-38 and Ser-72
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were mutated, PKA-mediated phosphorylation of vimentin was decreased in vitro and
disassembly was affected. Since some phosphorylation remained, this proved that other
sites were still being phosphorylated by PKA. This suggests that all of the PKA sites play a
role in the assembly state of vimentin (Eriksson et al., 2004).
Protein phosphorylation also plays a role in regulating integrins in motile cells.
PKC is one serine/threonine kinase that regulates integrins, and this affects adhesion and
migration (Woods, White, Caswell, & Norman, 2004). PKCe is responsible for a part of
the endocytic pathway that allows integrin recycling to the plasma membrane. Without
PKCe, fibroblasts decrease movement, and there is an emergence of ß1 integrin/PKCecontaining vesicular structures, which resemble a transient recycling compartment.
Research showed that vimentin was targeted for phosphorylation by PKCe in these integrin
intracellular vesicles, and this phosphorylation controls the integrins exiting this
compartment to the plasma membrane. When PKCe is inhibited, there is a decrease in
acidic vimentin and a decrease in serine phosphorylation (Ivaska, Whelan, Watson, &
Parker, 2002). It is likely that PKCe and vimentin are released from the vesicles as a
complex. An experimental release assay showed Ser6 phosphorylation combined with the
other serine residues in the amino-terminal of the PKC mediated cluster of vimentin had a
positive effect. Further experiments showed that vimentin influences the migration of cells
in a PKCe dependent manner because of the increase in migration seen in PKCe reexpressing cells compared to PKCe null cells. An additional experiment mutated serine
residues to alanine to analyze the importance of the N-terminus and the other PKC-sites on
vimentin induced cell motility. The researchers also substituted the serines (S4, 6, 7, 8, 9)
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with aspartate, which are negatively charged residues and mimic PKCe phosphorylation.
The alanine mutation, which is unphosphorylatable, prevented motility, while the aspartate
mutation restored motility. The alanine mutation interfered with vimentin filament
assembly and caused a buildup of integrin and PKCe positive vesicles comparable to
results when PKC activity is inhibited. This showed that PKCe mediated phosphorylation
at the N-terminus of vimentin plays a large role in PKCe dependent, vimentin induced cell
motility. The mutant vimentin caused decreased recycling of integrins as well, which
implies that endocytosed integrin/PKCe containing vesicles link with vimentin. These
integrins exit and recycle to the plasma membrane from this vesicle dependent on PKCmediated phosphorylation of vimentin (Ivaska et al., 2005).
Another phosphorylation site identified on vimentin is Ser-72. Intermediate
filament bridges are very common when there are mutations in Rho-kinase, PKC
phosphorylation sites, and Ser-72. Of these three, mutation of vimentin at Ser-72 is the
most critical mutation site. Experiments demonstrated that phosphorylation of vimentin at
Ser-72 was not present in Aurora-B (K/R)- expressing cells, which implied that
phosphorylation of vimentin at Ser-72 is controlled by Aurora-B. This phosphorylation by
Aurora-B could be involved in segregation of vimentin filaments during cytokinesis. It was
also suggested that cleavage furrow-specific intermediate filament phosphorylation could
be mediated by both Rho-kinase and Aurora B (Goto et al., 2003).

14
Nuclear Factor-?B (NF-?B)
NF-?B is a transcription factor widely recognized to be involved in carcinogenesis
and control of the immune and inflammatory responses. NF-?B regulates a variety of
target genes that are involved in cell proliferation, regulating apoptosis, facilitating
angiogenesis, and inducing invasion and metastasis. It has a conserved 300 amino acid Rel
homology domain in the N-terminus. This domain is involved in DNA binding,
dimerization, and interacting with I?B proteins, which are inhibitory factors (Lee, Jeon,
Kim, & Song, 2007). Inactive NF-?B proteins are prevalent in most cells, and they are
contained in the cytoplasm in a complex with I?B. I?B kinase is involved in all of the
extracellular signals that activate NF-?B. When activated by DNA damage, cytokines, or
growth factor signaling, I?B kinase phosphorylates serine residues on I?B (Loercher et al.,
2004). Next, I?B is ubiquitinated and degraded by a proteasome, and NF-?B is exposed to
nuclear- localization signals. This allows NF-?B to translocate to the nucleus and initiate
transcription of a variety of target genes. Ultimately, the NF-?B signaling is stopped by a
negative feedback loop. One of the genes NF-?B transcribes is I?B, so the level of I?B
increases and binds with NF-?B in the nucleus, and the complex migrates back to the
cytosol (Lodish, 2004). This is called the classical or canonical pathway and is triggered by
infection or proinflammatory cytokines. The classical pathway is important for innate
immunity and inhibiting apoptosis. The alternative or non-canonical pathway is initiated
by members from the TNF cytokine family to activate IKKa homodimers by NF-?Binducing kinase. This pathway is a part of secondary lymphoid organ development and the
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adaptive immune response. The atypical pathway does not require I?B and is initiated by
UV radiation that damages DNA or doxorubicin (Lee et al., 2007).

Figure 1: The canonical NF-?B signaling pathway.
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Nuclear Factor-?B (NF-?B) – Involvement in Cancer
NF-?B is capable of inducing several of the six hallmarks of cancer and has also
been found constitutively activated in some cancer cells. This activation could result from
several mechanisms. Viral onco-proteins are capable of constitutively activating NF-?B.
Changes such as translocations, deletions, and mutations potentially interrupt the genes
that regulate activation causing constant NF-?B activation. Proinflammatory cytokines
stimulated by autocrine or paracrine feedback, as well as activation of signaling molecules
can stimulate I?B activity resulting in constitutive activation of NF-?B. Supporting cancer
cell proliferation, avoiding apoptosis, and amplifying tumor angiogenic and metastatic
potential are all results of constitutively activated NF-?B transcription factors. NF-?B
regulates cell proliferation by activating target genes that control growth factors and
promote proliferation of lymphoid and myeloid cells. NF-?B is also linked to cyclin D1
(Karin, Cao, Greten, & Li, 2002). Cyclin D1 is a G1 specific cyclin, which promotes
progression through the restriction point during the G1 phase of the cell cycle (Kim &
Diehl, 2009). There is a NF-?B site in the cyclin D1 promoter, and this initiation of cyclin
D1 supports the proliferation of mammary epithelial cells throughout pregnancy (Karin et
al., 2002). There is overexpression of cyclin D1 in about 80% of HNSCC. Experiments
show that inhibiting NF-?B results in decreased cell cycle progression, and this can be
reversed by transfection and expression of a cyclin D1 plasmid (Allen, Ricker, Chen, &
Van Waes, 2007). NF-?B is also able to inhibit apoptosis. Several anti-apoptotic factors
induced by NF-?B include caspase-8/FADD (FAS-associated death domain)- like IL-1ß
converting enzyme (FLICE) inhibitory protein (cFLIP) and members of the BCL2 family.
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Constitutively activated NF-?B stops the apoptotic response to anticancer drugs and
radiation. NF-?B anti-apoptotic effects can facilitate the formation of neoplasms by
making cells that have had chromosomal rearrangements or other DNA damage more
resistant to cell death. Additionally, chemokines play an important role in angiogenesis,
and cells with increased levels of NF-?B have elevated production of some proangiogenic
chemokines. This results in greater migratory activity. IL-8 is a chemokine regulated by
NF-?B that is involved in enhancing angiogenesis (Karin et al., 2002). It has a NF-?B
binding site in its promoter, which is elevated in patients with HNSCC (Allen et al., 2007).
Also, activation of NF-?B plays a role in destruction of the extracellular matrix by cancer
cells (Karin et al., 2002). Blocking NF-?B activity has shown decreased angiogenesis,
invasion, and metastasis (Lee et al., 2007). Furthermore, matrix metalloprotease-9 (MMP9) is commonly overexpressed in HNSCC. MMP-9 requires NF-?B for expression, and
higher levels of MMP-9 are associated with nodal metastasis. Furthermore, cigarette
smoke condensate causes NF-?B activation by phosphorylation and degradation of I?B,
which is consistent with why smoking is a risk factor for HNSCC (Allen et al., 2007).
Since NF-?B plays a role in inhibiting apoptosis and promoting tumor progression
and is found constitutively activated in many cancers, NF-?B inhibitors could be useful in
cancer therapy. However, NF-?B inhibitors are not very specific and inhibit other
necessary signaling systems. Since NF-?B is activated by a variety of pathways, the
likelihood of a single inhibitor to affect all tumors is low (Lee et al., 2007). Current
inhibitors target the proteosome, I?B, and kinases upstream with a role in NF-?B
activation. Clinical and preclinical studies have shown anticancer activity with these
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agents. Bortezomib (PS-341) inhibits the proteasome and has improved results with
radiation in metastatic HNSCC (Ferris & Grandis, 2007). This drug has shown decreased
expression of cyclin D1, Bcl- XL, and IAP-1, which are all regulated by NF-?B in HNSCC
(Allen et al., 2007). Inhibition of NF-?B has been shown to stop proliferation, cell survival,
migration, angiogenesis, and tumorigenesis. All of this suggests that NF-?B modifies the
gene expression profile and malignant phenotype (Loercher et al., 2004).

Wnt-dependent Signaling Pathway
The Wnt-dependent signaling pathways consist of three molecular pathways
downstream of the Wnt/Frizzled (Fzd) interaction. The “canonical” Wnt pathway involves
Wnt and ß-catenin. The “non-canonical” pathways consist of Wnt/Ca2+ and Wnt/polarity.
Wnt Pathway

Wnt Ligands for Activation

Wnt/ß-catenin - “canonical”

Wnt 1, 3A, 8 and 8B

Wnt/Ca2+ - “non canonical”

Wnt 4, 5A, and 11

Wnt/polarity - “non canonical”

Wnt 4, 5A, and 11

Table 1: Wnt Pathways and Wnt Ligands for Activation

Although each pathway is different, they share the same initial step of the Wnt
ligand binding to the appropriate Fzd receptor. The Fzd receptor is a seven pass
transmembrane receptor. The human genome contains nineteen Wnt ligands and ten
different members of the Fzd seven-transmembrane receptor family. There are four
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families of Wnt antagonists that have been assigned to two groups based on their mode of
action. Secreted Frizzled related protein (sFRP) family, Wnt inhibitory factor-1 (WIF-1)
and Cerberus are the first group. This group inhibits Wnt signaling by directly binding to
the Wnt molecules. The Dickkopf (DKK) family makes up the second group, and they
inhibit Wnt signaling by binding to the LRP5/LRP6 component of the Wnt receptor
complex (Janssens, Janicot, & Perera, 2006). The Wnt signaling pathway is involved in
several important developmental events, including brain development, limb patterning, and
organogenesis. This pathway also regulates formation of osteoblasts and controls stem
cells. Interruptions in this signaling pathway are found in multiple cancers (Lodish, 2004).

Figure 2: The Wnt/ß-catenin signaling pathway. (Left) A schematic showing the absence
of a Wnt ligand. (Right) A schematic showing the presence of a Wnt ligand.
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ß-catenin, a cytoplasmic protein, is the central molecule in the Wnt/ß-catenin
pathway. This pathway affects several cellular processes including cell adhesion, growth,
and differentiation (Du et al., 2009). For this pathway, an additional single-pass
transmembrane protein from the low-density lipoprotein receptor family (LRP5 or LRP6)
serves as a co-receptor of the seven transmembrane Fzd receptors to conduct the Wnt
signal. Activation of the pathway begins with Wnt binding to the receptor complex
consisting of the Fzd receptor and LRP co-receptor (Janssens et al., 2006). Wnt signaling
inhibits the multi-protein ß-catenin degradation complex. This complex is formed by the
scaffold protein axin, the serine/threonine kinase glycogen synthase kinase 3ß (GSK3ß),
the tumor suppressor protein APC, and ß-catenin (Kühl, 2003). Once Wnt is bound,
dishevelled (Dvl) is phosphorylated, and its relationship with axin inhibits GSK3ß and
casein kinase 1a (CK1a) from phosphorylating important substrates such as ß-catenin.
Phosphorylation of ß-catenin is required for its degradation. Without phosphorylation, ßcatenin localizes to the nucleus, forms a complex with TCF/LEF (T-cell factor/lymphoid
enhancer factor) transcription factors and other co-activators that allow expression of
downstream target genes. When the Wnt/Fzd signal is not present, GSK3ß and CK1a
phosphorylate ß-catenin, which targets it for degradation. Thus, ß-catenin will not collect
in the nucleus, so TCF/LEF proteins serve as transcriptional repressors (Janssens et al.,
2006).
Multiple studies have shown that abnormal Wnt/ß-catenin signaling is involved in
human cancer. In colon cancer, a mutation in APC causes ß-catenin to buildup in the
cytoplasm and enter the nucleus. This causes increased proliferation and carcinogenesis by
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ß-catenin interacting with TCF-4/LEF (Du et al., 2009). A transgenic mouse model has
suggested that Wnt-1 expression supports tumor growth, and there is evidence in human
breast cancer showing Wnt signaling promotes tumor development. When Wnt1 is
expressed, cells are resistant to cancer therapies based on apoptosis by inhibiting ßcatenin/TCF mediated transcription. Studies have shown advantages for blocking Wnt
signaling in cancer patients, because inhibiting the Wnt/ß-catenin signaling pathways
allows apoptosis and chemotherapy to work more effectively (Janssens et al., 2006). The
Wnt/ß-catenin pathway has also been shown to regulate the transcription factor Twist in
mouse mammary epithelial cell lines and tumors. Twist and Wnt1 can both inhibit
lactogenic differentiation, which possibly causes mammary tumorigenesis (Howe,
Watanabe, Leonard, & Brown, 2003). Wnt5a is involved in cell motility and invasion in
metastatic melanoma, because when its receptor is blocked, PKC activity and cellular
invasion are inhibited (Janssens et al., 2006). Wnt5a has been classified as a gene more
prevalent in highly aggressive tumors compared to less aggressive tumors. This member of
the Wnt family is independent of ß-catenin and acts through the non-canonical Wnt
signaling pathway by binding a G-protein-coupled receptor to activate PKC and
intracellular calcium. Increasing Wnt5a in melanoma cells resulted in increased PKC
activation and motility and poor patient outcome. Wnt5a increases vimentin expression
and decreases E-cadherin. Experiments demonstrated Wnt5a could increase metastatic
melanoma through initiating EMT in a PKC-dependent manner (Dissanayake et al., 2007).
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ß-catenin
In normal epithelial cells, ß-catenin is found in complexes with E-cadherin and
plays a part in cell-cell adhesion. ß-catenin is also found accumulating in the cytoplasm or
translocating to the nucleus. Both of these locations are associated with epithelial cell
migration and EMT. Several genes are targeted by ß-catenin/TCF transcription, including
MMP-7, c-myc, and cyclin D1 (Gilles et al., 2003). The ß-catenin promoter includes NF?B DNA binding motifs (Loercher et al., 2004). ß-catenin can act as an oncoprotein in
several cancers, and mutations in the region of the gene encoding the amino terminal of ßcatenin can affect the serine and threonine residues involved in phosphorylation by GSK3ß
and CK1 that label ß-catenin for degradation. Both APC and axin are important for downregulation of ß-catenin (Janssens et al., 2006). Crosstalk also exists in bacterial-colonized
HCT116 intestinal epithelial cells between NF-?B and ß-catenin. Constitutively expressed
ß-catenin stabilizes I?Ba indirectly which results in NF-?B inhibition (Du et al., 2009).
Vimentin expressing cells have a larger amount of ß-catenin/TCF transcriptional activity
than vimentin- negative cells, and experiments support vimentin as a target of the ßcatenin/TCF pathway. The human vimentin promoter is reported to contain a ßcatenin/TCF binding site 468 bp upstream of the transcriptional start site. In mammary
human epithelial cell lines, the localization of ß-catenin in the cytoplasm and nucleus is
associated with vimentin expression and is restricted to invasive or migrating cells (Gilles
et al., 2003).
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The Dickkopf Family
The Dickkopf family consists of secreted proteins ranging in size from 255 to 350
amino acids, and there are four main forms found in vertebrates. DKK-1 and DKK-4 are
pure Wnt/ß-catenin inhibitors. DKK-2 and DKK-3 can activate or inhibit the Wnt/ßcatenin pathway depending on the cellular context. Members of the DKK family inhibit
through two mechanisms. The first mechanism involves DKK directly binding to LRP5/6
and blocking the Wnt-LRP interaction. The second mechanism requires the DKK family
member forming a complex with LRP5/6 and the DKK receptor Kremen. This complex
causes endocytosis, and LRP5/6 is removed from the plasma membrane, which inhibits the
Wnt/ß-catenin pathway (Pendas-Franco, Aguilera, Pereira, Gonzalez-Sancho, & Munoz,
2008).

Dickkopf-3 (DKK-3)
DKK-3 is found on chromosome 11p15, and this region is a significant target of
methylation- mediated genetic imprinting (Yu et al., 2009). High levels of DKK-3 have
been found in tumor endothelial cells of glioma, high-grade non-Hodgkin’s lymphomas,
melanoma, and colorectal cancers. Additionally, DKK-3 is a potential marker during tumor
angiogenesis for endothelial cell activation (Pendas-Franco et al., 2008). DKK-3 is a strong
regulator of cell invasion, but can be transcriptionally inhibited in a membrane type-1MMP (MT1-MMP) dependent manner. This member of the DKK family serves as a tumor
suppressor by halting cell growth and motility. In urothelial cell carcinoma, DKK-3 assists
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inhibition of the Wnt signaling pathway, which results in tumor suppression (Saeb-Parsy et
al., 2008). The absence of DKK-3 can allow activation of the Wnt signaling pathway and
support tumor growth through disregulation of cell proliferation and differentiation. It is
possible that down-regulation of DKK-3 in various cancers occurs as a result of promoter
methylation. This is the common reason for decreased DKK-3 expression in gastric and
colon cancers, and DKK-3 is often reduced or silenced in gastric and colon cancer cell
lines (Yu et al., 2009). Methylation of the DKK-3 promoter in primary gastric cancer was
associated with poor patient outcome. Studies showed that the decreased expression of
DKK-3 in colon cancer cells is caused by promoter methylation. DNA- methyltransferase
activity inhibited by 5-aza-2’-deoxycytidine (5-Aza-dC) reversed the methylation, and the
silenced gene was re-expressed. There was an increase in DKK-3 mRNA expression in the
silenced cell lines once treated with 5-Aza-dC supporting that methylation was the major
cause of decreased DKK-3 expression in digestive cancer cells. Constant expression of
DKK-3 results in decreased colony formation. This inhibition by DKK-3 on cell growth
has also been shown in lung cancer and osteosarcoma cells (Yu et al., 2009).

Previous Research in Our Lab
Previous research in our lab has shown that HN12 cells, derived from a lymph node
metastasis, express a higher level of vimentin than HN4 cells, derived from a primary
tumor on the tongue. HN12 cells also have decreased expression of several keratins,
including K13, K14, and K15. RNA interference was used to inhibit vimentin expression
in HN12 cells to determine the effects of vimentin overexpression, and this inhibition
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resulted in decreased proliferation, migration, and invasion. Additionally, these vimentin
knockdowns showed an up-regulation of K13, K14, and K15. In athymic mice, these cells
showed smaller and more differentiated tumors. Through quantitative PCR and promoter
assays, the data showed that the re-expression of these keratins in the vimentin knockdown
cells was a result of increased transcription (Paccione et al., 2008).
Additional studies in our lab have demonstrated that DKK3, a Wnt antagonist, is
inhibited by promoter methylation in HN12 cells. With 5-aza-2’-deoxycytidine, this
inhibition is relieved, and there are decreased levels of ß-catenin transcriptional targets.
Other studies have shown that ß-catenin increases vimentin expression through Wnt
signaling (Gilles et al., 2003). This suggests that by inhibiting DKK3, Wnt signaling could
increase vimentin expression, and this could cause decreased keratin expression. Currently,
the mechanism for the repression of keratins in the presence of vimentin overexpression is
unknown.

26

Figure 3: A. DKK3 promoter is methylated and transcription is inhibited. B. DKK3 is
expressed which blocks the Wnt signaling pathway.

Hypothesis
The downregulation of differentiation-specific keratins contributes to tumor
progression, mediated directly or indirectly by expression of vimentin.

Aims of the Current Study
•

To determine keratin gene expression and biological response in cells that express
wild-type and PKC phosphorylation site mutants of vimentin
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o Vimentin will be expressed in vimentin-negative tumor cells and expression
of K14 will be determined by western blot and qPCR.
o Proliferation rate will be determined by cell counting.
o Effects on cell motility and invasion will be determined by wound-closure
assays.
•

To determine the role of Wnt signaling in vimentin expression during EMT.
o Determine the effect of NF?B inhibitor on HN12 cell growth.
o Determine the effect of 5-Aza-C on HN12 cell growth.
o Proliferation will be determined by cell counting.
o 5-azaC will be used to relieve the repression on the DKK3 promoter in cells
where it is repressed by methylation.
o Vimentin expression will be determined.

Methods
Cell Culture
HN4 cells were obtained from a primary squamous cell carcinoma of the tongue.
HN12 cells were obtained from a nodal metastasis in the same patient. HNSCC cells lines
were cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM) containing 10%
fetal bovine serum (FBS), penicillin-streptomycin (10µg/ml), and L-glutamine (10µg/ml).
All cells were maintained at 37°C in 90% air/10% CO2.

Growth Factors and Inhibitors
HN4 cells expressing the vimentin mutations generated by transfection were
cultured as above in the presence of G418 (400µg/mL). HN4 shDKK3 cells were cultured
in DMEM in the presence of puromycin (1µg/ml). NF-?B inhibitor was prepared in
DMSO as a stock solution of 2mM. 5-Aza-dC was prepared in PBS as a stock solution of
6mM.

Plasmids
The plasmids pCMV Vim-Wt, pCMV Vim-Ala, and pCMV Vim- Asp encode
amino acid substitutions at serines 4,6,7,8,9. In pCMV Vim- Ala, these serine residues have
been mutated to alanine, and pCMV Vim-Asp has these serine residues have been mutated
to aspartate. These plasmids have been described previously (Ivaska et al., 2005).
28

29

Bacterial Transformation
The plasmids pCMV Vim-Wt, pCMV Vim-Ala, and pCMV Vim- Asp were
supplied on filter paper. 100 µL of 1 x TE buffer was added to each plasmid and briefly
vortexed. These were stored at 4°C overnight. For bacterial transformation, the plasmids
were centrifuged for 2 min at 15.4 rpm, and the competent E. coli cells were thawed on ice
for 10 min. 5µl of each sample was combined with 50µl of competent cells (Bioline,
Randolph, MA). 1µl of the control pUC19 (Bioline, Randolph, MA) was added to the
competent cells. Samples were placed on ice for 30 min, then heat shocked at 42°C for 45
s, and immediately placed on ice for 2 min. 250µl of SOC was added to each tube, and
samples were placed in the shaker at 37°C for 1 h. The entire sample was added to an agar
plate containing kanamycin (50µg/mL), then spread using glass beads. The plates were
incubated for 15 min at room temperature, and then incubated overnight at 37°C.

Isolating Colonies and Establishing Liquid Cultures
Colonies were picked from the plates after incubating overnight. A single colony
was combined with 3mL of 2 x YT medium in a 15mL tube and shaken overnight at 37°C.

Small Scale DNA Preparations
Small scale DNA preparations (Minipreps) were carried out using the Promega
Wizard Plus SV Miniprep DNA Purification System (Promega, Madison, WI). This
isolated the plasmid DNA from the transformed E. coli. Initially, 1.5 mL of the bacterial
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culture was centrifuged at 10,000 x g for 5 min. The supernatant was poured off, and 250
µL of Cell Resuspension Solution was added to resuspend the pellet. The solution was
briefly vortexed. Next, 250 µL of Cell Lysis Solution was added to each sample and mixed
by inverting the tube 4 times. Samples were incubated at room temperature for 5 min. 10
µL of Alkaline Protease Solution was added to each sample and mixed by inverting the
tube 4 times. The samples were incubated at room temperature for another 5 min. 350 µL
of Neutralization Solution was added and immediately inverted 4 times to mix. The
samples were centrifuged at 14,000 x g for 10 min. The cleared lysate was transferred to a
spin column by decanting to avoid transfer of the white precipitate. The supernatant was
centrifuged for 1 min at 14,000 x g. The spin column was removed from the tube, and the
flowthrough was discarded from the collection tube. Next, the spin column was placed
back in the collection tube. 750 µL of Column Wash Solution was added to each spin
column and centrifuged for 1 min at 14,000 x g. The flowthrough was discarded as before,
and the procedure was repeated with 250 µL of Column Wash Solution. The samples were
spun for 2 min at 14,000 x g, then the spin column was transferred to a new, sterile 1.5 mL
microcentrifuge tube. The plasmid DNA was eluted by adding 100 µL of Nuclease-Free
Water to the spin column and centrifuged at 14,000 x g for 1 min. The spin column was
discarded, and the eluted DNA was stored at 4°C.
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Larger Scale DNA Preparations
Larger scale DNA preparations (Midipreps) were carried out using the Promega
Wizard Plus Midiprep DNA Purification System (Promega, Madison, WI). This isolated
the plasmid DNA from the transformed E. coli. The cells were centrifuged at 10,000 x g
for 10 min at 4°C to form a pellet. The pellet was resuspended with 3mL of Cell
Resuspension Solution. Next, 3mL of Cell Lysis Solution was added to each sample and
inverted to mix, followed by 3mL of Neutralization Solution and inverted. The samples
were centrifuged at 14,000 x g for 15 min at 4°C, and the supernatant containing the DNA
was decanted. The resin was reuspended by adding 10mL of resin to the DNA and mixed
by swirling. Next, the midicolumn was connected to the vacuum manifold. The resin/DNA
mixture was transferred to the midicolumn, and the vacuum was applied. The vacuum was
released once all of the liquid passed through the column. 15mL of Column Wash Solution
was added to each sample, and the vacuum was applied. This washing step was repeated,
and once all of the liquid passed through the column, the vacuum was left on for an
additional 30 s. The midicolumn was removed from the vacuum and placed in a 1.5mL
microcentrifuge tube, where it was centrifuged for 2 min at 10,000 x g. After being spun
down, the midicolumn was transferred to a new microcentrifuge tube, and 300µL of
preheated water was added to each sample. The samples incubated for 1 min and were
centrifuged at 10,000 x g for 20 s to elute the DNA. The elutate was centrifuged for 5 min
at 10,000 x g to pellet the resin fine. The supernatant that contained the DNA was
transferred to a new microcentrifuge tube and stored at -20°C.
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Nuclear Transfection
The pCMV Vim-Wt, pCMV Vim- Ala, and pCMV Vim- Asp plasmids were
transfected into HN4 cells using the Lonza Nucleofector Kit (Lonza Inc., Gaithersburg,
MD) using 4 µg of midiprep DNA. HN4 cells were trypsinized, counted, and distributed
into four tubes (2 x 106 cells per tube). Each tube was centrifuged, and the medium was
aspirated. The cell pellet was resuspended with 100 µL of Nucleofector Solution and
transferred to a cuvette. 4µg of plasmid DNA and 0.5µg GFP plasmid were added to each
cuvette. The cuvette was inserted into the Nucleofector, and the cells were transfected
using program T-20. Once the transfection was complete, the cuvette was removed from
the machine, and 500 µL of warm medium with serum was added. This suspension was
transferred to a 10 mm plate containing 10 mL of complete growth medium. The GFP
plasmid was added to serve as an internal control for transfection efficiency.

Transient Transfection
The pCMV Vim-Wt, pCMV Vim- Ala, pCMV Vim- Asp plasmids and GFP, as a
control, were transfected into 293T cells to confirm expression. 5 x 104 cells were plated
per well in a 6-well plate for 24 h in complete growth medium. In a sterile microcentrifuge
tube, 3 µL/µg of Trans IT-Keratinocyte Transfection Reagent (Mirus, Madison, WI) was
added dropwise into 200 µL of serum- free medium and mixed by vortexing. This solution
was incubated for 20 min at room temperature. 2 µg of DNA was added to the diluted
Trans IT-Keratinocyte Reagent and mixed by gentle pipetting. This solution was again
incubated for 20 min at room temperature. Next, the medium was removed from the 293T
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cells and replaced with 2 mL per well of fresh complete growth medium. The Trans ITKeratinocyte Reagent/DNA complex mixture was added dropwise to the 293T cells. The
plate was gently rocked to evenly distribute the mixture in the wells and incubated at 37°C
for 48 h.

Western Blot
Total cellular protein extracts were prepared as follows. Cells were washed with
cold PBS two times, and then 50µL of vimentin lysis buffer was added to each well. After
incubating 10 min on ice, the samples were collected and centrifuged for 10 min at 4°C
and 10.4 rpm. 12.5 µL of 5 x SDS-PAGE buffer was added to each sample. The samples
were heated for 10 min at 100°C, and then placed on ice for 2 min. The lysates were
resolved by 10% SDS-polyacrylamide gel (Sambrook & Russell, 2001) electrophoretically
at 120 V in 1 x SDS-PAGE running buffer. Fractionated proteins were transferred to
PVDF membranes (Immobilon-P, Millipore Corporation, Bedford, MA) overnight in 1 x
transfer buffer. The membranes were blocked in 5% non- fat dried milk in 0.05% TweenTBS (T- TBS) for 1 h at room temperature, washed three times for 5 min with 0.05% TTBS, and incubated overnight with the primary antibody on a shaker at 4°C. Next, the
membranes were washed three times with TTBS for 5 mins. After washing, the membranes
were incubated with HRP-conjugated secondary antibodies at room temperature for 1 h.
The membranes were washed again with TTBS three times for 5 min. Finally, the
membranes were incubated at room temperature for 2 min with Western Lightning
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Chemiluminescence Reagent Plus (Perkin Elmer Life Sciences Inc., Boston, MA) and
imaged using Kodak film.
Primary Antibody
Vimentin
Keratin 14 (hybridoma
supernatent)
Actin

Supplier
Dilution
Sigma, St. Louis, MO
1:5000
Gift of Dr. A. Waseem,
1:1000
University of London
Santa Cruz Biotechnology,
1:1000
Santa Cruz, CA
Abcam, Cambridge, MA
1:500
Table 2: Primary Antibodies for Western Blotting

DKK3

Immunofluorescence
Cells (5 x 103 ) were plated on coverslips in 12-well plates and allowed to grow
until 75% confluent. Cells were washed with PBS, and then fixed in cold methanol for 20
min. The cells were permeabilized in PBST (PBS and Triton X) for 5 min, and then
blocked in 5% BSA in PBST for 1 h at room temperature. Cells were incubated with the
primary antibody diluted in blocking buffer overnight at 4°C. The cells were washed six
times for 5 min with PBST and incubated with a FITC-conjugated secondary antibody at a
1:500 dilution in blocking buffer and 1µg/mL DAPI for 1 h at room temperature. The
coverslips were mounted on a microscope slide with Vectashield and analyzed with a Zeiss
Axiovert 200 inverted fluorescence microscope.
Primary Antibody
Vimentin
Keratin 14 (hybridoma
supernatent)
? -catenin
E-cadherin

Supplier
Dilution
Sigma, St. Louis, MO
1:500
Gift of Dr. A. Waseem,
1:250
University of London
Santa Cruz Biotechnology,
1:100-1:200
Santa Cruz, CA
Sigma, St. Louis, MO
1:100-1:200
Table 3: Primary Antibodies for Immunofluorescence
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MTT Assay
Cells were plated at 5x103 cells per well in a 12-well plate in triplicate and allowed
to grow to 80% confluence. 100 µL of MTT reagent (3-(4,5-Dimethylthiazolyl-2)-2,5Diphenyl Tetrazolium Bromide in PBS) (MP Biomedicals Inc., Solon, OH) was added to
each well, and the cells incubated for 4 h at 37°C in 90% air/10% CO2 . The medium and
reagent were removed from each well, and the formazan crystals were solubilized in 1 mL
of MTT solubilization buffer (0.01M HCl with 10% SDS) per well and incubated
overnight. Absorbance was measured spectrophotometrically at 570 nm. The MTT
solubilization buffer was used as the blank measurement.

Cell Proliferation Assay
Cells were plated at 5 x 103 cell per well in 6-well plates. They were cultured for
three days before counting and counted for five consecutive days using a hemacytometer.
Each cell line was plated in triplicate, and each well was counted twice. For counting, the
cells were trypsinized with 250 µL trypsin and incubated until all of the cells were
detached. The trypsin-cell suspension was neutralized with 1 mL of medium and
centrifuged at 1.0 rpm for 5 min. Cells were resuspended in 0.1 mL, 0.5 mL, or 1 mL of
medium and counted.
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RNA Extraction
Cells were plated in 6-well plates and allowed to grow until they were 75%
confluent. The medium was removed, and 1 mL of Trizol reagent (Life Technologies,
Carlsbad, CA) was added to each well. The plate was incubated for 5 min on a shaker.
After incubating, the entire contents of the well were transferred to a microcentrifuge tube
and incubated for 2 min, then 200 µL of chloroform was added to each tube. The tubes
were shaken vigorously by hand, and then centrifuged at 4°C for 15 min at 12,000 x g. The
clear aqueous phase was carefully pipetted to a new microcentrifuge tube. 0.5 mL of
isopropyl alcohol was added to each tube and incubated at room temperature for 10 min.
The samples were centrifuged at 4°C for 15 min at 12,000 x g. The supernatant was
removed, and the pellets were washed with 1 mL of 75% ethanol. Next, the samples were
centrifuged at 4°C for 5 min at 12,000 x g. The supernatant was removed, and the pellets
air-dried for 30 min. The pellet was then resuspended in 20 µL of RNase-free water. The
samples were heated at 55°C for 15 min, chilled on ice for 2 min, and then briefly
centrifuged. The RNA concentration was measured using a Nanodrop spectrophotometer.
The RNA, at a concentration 1µg/µL, was electrophoresed in a 1% agarose gel to
determine the quality of the sample.

cDNA Synthesis
cDNA was synthesized from extracted RNA using MultiScribe Reverse
Transcriptase (Applied Biosystems, Foster City, CA). In a labeled microcentrifuge tube, 2
µg RNA, 1 µL of 100µM oligo(dT), 1 µL of 10mM dNTP were added, and then milliQ
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water was added until the total volume was 13 µL. The samples were incubated at 65°C for
5 min, then placed on ice for 2 min. After briefly centrifuging the samples, 4 µL of 5 x
First Strand Buffer and 2 µL 0.1 M DTT were added to each microcentrifuge tube. The
samples were briefly centrifuged again, and 1 µL of MultiScribe Reverse Transcriptase
was added to each tube and mixed by pipetting. The samples were incubated in a water
bath at 42°C for 50 min, and the reaction was stopped by heating at 70°C for 15 min. The
samples were chilled on ice for 2 min, briefly centrifuged, and then stored at -20°C.

Polymerase Chain Reaction (PCR)
Each reaction consisted of 5 µL 10x High Fidelity PCR Buffer, 1 µL 10 mM dNTP,
2 µL 50 mM MgSO4 , 1µL primer, 1 µL template DNA, 0.2 µL Platinum Taq High Fidelity
DNA polymerase, and 40 µL nuclease- free water. A master mix was made which
contained the appropriate amounts of the above reagents for the number of reactions being
run with the exception of the template DNA. 49 µL of the master mix was placed into each
microcentrifuge tube, and 1 µL of template DNA was added to each tube individually. The
samples were briefly centrifuged and placed in the GeneAmp PCR System 9700 thermal
cycler. The cycle settings were denature at 94°C for 30 s, anneal at 55°C for 30 s, and
extend at 68°C for 1 min. A total of 40 cycles were run, and the samples cooled at 4°C
after cycling.
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Quantitative Real- Time Polymerase Chain Reaction (qRT-PCR)
All qRT-PCR reactions were performed using an ABI 7500 Fast System (Applied
Biosystems, Rockville, MD). Each reaction consisted of 5 µL SYBR-green mix, 1 µL
primer, 1 µL cDNA, and 3 µL nuclease- free water in a total volume of 10 µL. A master
mix lacking template was made which contained the appropriate amount of the above
reagents for the number of reactions being run. Each sample was run in triplicate. 9 µL of
the master mix was placed into each well, and 1 µL of cDNA template was pipetted
individually into each well. The 96-well plate was covered with an adhesive cover slip, and
then briefly centrifuged. The 7500 Fast Real-Time PCR System was used in the Standard
7500 mode using a SYBR- green protocol.

Immunoprecipitation
Cells were counted and plated in normal growth medium. After 24 h, cells were
washed with PBS and placed in serum- free medium. The conditioned medium was
collected from the cells and transferred to a microcentrifuge tube. 1µg DKK3 antibody was
added to each tube per 1mL of conditioned medium. The microcentrifuge tubes were
rotated end-over-end at 4°C for 30 min. Next, 30µL of a 50% slurry of Protein ASepharose was added to each sample and rotated end-over-end for 1h at 4°C. The samples
were centrifuged at 10,000 rpm for 5 min at 4°C. The supernatant was carefully decanted
from each sample. 1mL of lysis buffer was added to each tube, flicked to wash, and
centrifuged for 1 min. The process of removing the supernatant, washing, and centrifuging
was repeated twice. After the third wash, the samples were centrifuged again without any
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lysis buffer, and the remaining liquid was removed by careful pipetting. The Sepharose
complexes were resuspended in 1 x SDS/PAGE buffer, heated at 95°C for 10 min, and run
on a 10% SDS-polyacrylamide gel.

Cell Migration Assay
Cell migration was assessed using wound- healing (scratch) assays. Cells were
counted and plated in triplicate in 12 well plates. The cells were incubated at 37°C until
100% confluent. Once totally confluent, a sterile pipette tip was used to scratch the surface
of the well, which removed a layer of cells in the scratched line. Each well was washed
with PBS and replaced with growth medium. After making the scratch, the width was
determined by measuring three specific points under a 5 x objective using a light
microscope and AxioVision software (Carl Zeiss Microimaging, Thornwood, NY). Cells
were incubated at 37°C for 8 h or 24 h, at which time, the width was measured again at the
same points used at 0 h.

Statistical Analysis
Data were analyzed using Microsoft Excel and Graphpad QuickCalcs software
(http://www.graphpad.com/quickcalcs/). Paired T-tests were performed, and p-values were
compared to an a-value of 0.05 to be considered statistically significant. Error bars on the
figures represent the standard error of the mean.

Results
Overexpression of Vimentin in Vimentin- negative HN4 Cells
Previous research in our laboratory has shown that HN4 cells express low levels of
vimentin, while HN12 cells express high levels of vimentin. Using shRNA to inhibit
vimentin expression in HN12 cells, there was decreased proliferation and motility, as well
as re-expression of keratins (Paccione et al., 2008). The cause of keratin re-expression is
unknown, but it is possible that vimentin plays a role in this regulation directly or
indirectly. Furthermore, studies have shown that Wnt signaling can upregulate vimentin
expression through ß-catenin (Goto et al., 2003). Wnt-5a has been shown to increase cell
motility and vimentin expression in melanoma cells. These effects are partially dependent
on PKC activity (Dissanayake et al., 2007). Additionally, PKCe phosphorylates vimentin
and has been shown to be required for vimentin- induced cell migration. Cells with
unphosphorylatable versions of vimentin do not show increased motility (Ivaska et al.,
2005). To explore the possibility of vimentin regulation of keratin, we expressed plasmids
encoding wild-type vimentin, a PKCe-phosphomimetic (aspartate mutant) version of
vimentin, or an unphosphorylatable (alanine mutant) version of vimentin in vimentinnegative HN4 cells. Transfection was performed using a Nucleofector device, and stable
cell pools were isolated in media containing 400µg/mL G418. Vimentin overexpression
was determined by western blot analysis. As shown in Fig. 4, vimentin was overexpressed

40

41
in cells containing the wild-type vimentin plasmid compared to parental HN4 cells. This
overexpression was highest in clone 3, which was chosen for further experiments. Fig. 5
shows the overexpression of vimentin with the PKCe-phosphomimetic version of
vimentin. The strongest overexpression was shown in clone 4, and this clone was used for
subsequent studies. Overexpression of the unphosphorylatable version of vimentin is
illustrated in Fig. 6. Several clones showed an increased level of vimentin compared to
parental HN4 cells, but clone 5 was used for further experiments. Once these clones were
identified, vimentin and keratin expression were confirmed by western blot analysis. As
shown in Fig. 7, vimentin was readily detected in the HN12 cell lysates, not detectable in
the HN4 cell lysates, and detectable at lower levels in cell lysates from the HN4 vimentin
mutants. Additionally, keratin 14 expression was not detected in the HN12 cell lysates.
However, keratin 14 was detectable in the HN4 control and vimentin mutant cell lysates.
Keratin 14 expression was also confirmed by qRT-PCR, using keratin 14-specific primers.
Fig. 8 shows that keratin 14 is expressed in the HN4 vimentin mutants but at a decreased
level compared to HN4 control cells. Furthermore, immunofluorescence confirmed
vimentin and keratin 14 expression in the HN4 vimentin mutant cells (Figs. 9 and 10,
respectively). Vimentin staining was absent in HN4 control cells, and keratin 14 staining
was absent in HN12 cells. These data confirm that vimentin is overexpressed in HN4
vimentin mutant cells. It also confirms that there is a difference in the expression of keratin
14 in the HN4 vimentin mutant cells compared to vector-transfected HN4 cells.
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Figure 4: Vimentin is expressed in HN4 cells transfected with the plasmid encoding
wild-type vimentin. Total cell protein extracts were prepared as described in ‘Methods’
and analyzed for vimentin expression by western blotting (top panel). Levels of actin were
determined as a loading control (lower panel).
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Figure 5: Vimentin is expressed in HN4 cells transfected with the plasmid encoding a
PKCe-phosphomimetic (aspartate mutant) version of vimentin. Total cell protein
extracts were prepared as described in ‘Methods’ and analyzed for vimentin expression by
western blotting (top panel). Levels of actin were determined as a loading control (lower
panel).
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Figure 6: Vimentin is expressed in HN4 cells transfected with the plasmid encoding
an unphosphorylatable (alanine mutant) version of vimentin. Total cell protein extracts
were prepared as described in ‘Methods’ and analyzed for vimentin expression by western
blotting (top panel). Levels of actin were determined as a loading control (lower panel).
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Figure 7: Vimentin and keratin 14 expression in HN4 vimentin-transfected cells. Total
cell protein extracts were prepared as described in ‘Methods’ and analyzed for vimentin
expression (top panel) and keratin 14 expression by western blotting (middle panel).
Levels of actin were determined as a loading control (lower panel).
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Figure 8: Keratin 14 expression is decreased in HN4 vimentin-transfected cell lines.
Total RNA was extracted and reverse-transcribed to create cDNA, and then qRT-PCR was
performed as described in ‘Methods.’ The relative expression ratio represents the
expression of keratin 14 to the internal standard, actin.
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Figure 9: Confirmation of vimentin expression in HN4 vimentin mutant cells using
immunofluorescence. Cells were cultured on glass coverslips and fixed as described in
‘Methods.’ Cells were incubated with anti- vimentin antibody overnight then incubated
with a FITC-conjugated anti- mouse antibody for 1h and counterstained with DAPI.
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Figure 10: Confirma tion of keratin 14 expression in HN4 vimentin mutant cells using
immunofluorescence. Cells were cultured on glass coverslips and fixed as described in
‘Methods.’ Cells were incubated with anti-keratin 14 antibody overnight then incubated
with a FITC-conjugated anti- mouse antibody for 1h and counterstained with DAPI.
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Confirmation of Expression of Vimentin Mutants in 293T Cells
The pCMV Vim-Wt, Vim-Asp, and Vim- Ala plasmids were transiently transfected
into 293T cells to confirm vimentin expression. qRT-PCR was performed on the cDNA
template using vimentin-specific primers. Fig. 11 shows vimentin expression was higher in
all three cell lines transfected with the plasmid when compared to the GFP control. The
vimentin expression in the 293T cells transfected with the PKCe-phosphomimetic version
of vimentin (lower panel) was much greater than the wild-type and unphosphorylatable
versions of vimentin (upper panel). These data confirm that expression of these plasmids
increased vimentin expression.
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Figure 11: Vimentin expression in transiently transfected 293T cells confirmed by
qRT-PCR. The expression ratio is a result of the vimentin expression levels compared to
an internal standard, ?-tubulin. All three vimentin mutants displayed greater vimentin
expression than the GFP control. However, vimentin expression in the PKCephosphomimetic version of vimentin (lower panel) was higher than the vimentin
expression in the wild-type and unphosphorylatable version of vimentin (upper panel).
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Effect of Vimentin Overexpression in HN4 Cells on Cell Growth
The expression of vimentin in HN12 cells has been suggested to cause increased
proliferation, migration, and invasion when compared to HN4 cells or HN12 cells with
RNAi to inhibit vimentin expression (Paccione et al., 2008). To determine the effect of
vimentin overexpression in vimentin- negative HN4 cells, we performed an MTT assay on
these cells to determine cell growth and viability. Cells were counted, plated in triplicate,
and allowed to grow for 7 days. After 7 days, the MTT assay was performed, and the
absorbance was measured by spectrophotometer. As shown in Fig. 12, the cells with the
wild-type or PKCe-phosphomimetic versions of vimentin grew much faster than the cells
with the unphosphorylatable version of vimentin and HN4 vector cells. Additionally, the
growth of the cells with the unphosphorylatable version of vimentin was slightly slower
than the HN4 vector cells. Further study of the effect on growth was carried out using a
cell proliferation assay. Cells were plated in triplicate and counted over 10 days. Fig. 13
shows that cells expressing the wild-type or PKCe-phosphomimetic versions of vimentin
have significantly increased proliferation compared to HN4 vector control cells. Also,
proliferation of cells containing the unphosphorylatable version of vimentin is significantly
decreased in comparison to HN4 vector control cells. These results suggest that vimentin
phosphorylation may influence how vimentin regulates cell growth.
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Figure 12: Expression of vimentin mutants affects cell growth. Cells (5 x 103 per well)
were plated in triplicate in 12-well plates and incubated as described in ‘Methods.’ After 7
days, the MTT assay was performed.
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Figure 13: Expression of vimentin mutants affects cell proliferation. Cells (5 x 103 per
well) were plated in triplicate in 6-well plates and incubated as described in ‘Methods.’
Cell counting began 4 days after cells were plated, and they were counted every other day
until day 10.
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Effect of Vimentin Overexpression in HN4 Cells on Cell Motility
After determining the effect of vimentin overexpression on proliferation of HN4
cells, we were interested to find out whether this overexpression also affected cell motility.
To determine the effect of vimentin overexpression on cell motility, we performed a
wound-healing (scratch) assay. Cells were counted, plated in triplicate, and allowed to
grow until 100% confluent. The wells were scratched with a sterile pipette tip, and the
width of the scratch was measured using a light microscope. Once the scratch was
measured at 0h, the cells were re-placed in the incubator, and the scratch was measured
again 8h or 24h later. As shown in Fig. 14, the cells with wild-type or PKCephosphomimetic versions of vimentin migrated at a faster rate than the HN4 vector cells.
Additionally, the cells with the unphosphorylatable version of vimentin migrated at a rate
similar to the HN4 vector cells.
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Figure 14: Expression of Vimentin Mutants Affects Cell Motility. Cells were plated in
triplicate in 12-well plates and incubated under standard conditions. Wells were scratched,
and the width was measured as described in ‘Methods.’
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Effect of Vimentin Overexpression in HN4 Cells on the Presence of ß-catenin
Research shows that ß-catenin can stimulate vimentin expression (Gilles et al.,
2003). Since we have overexpressed vimentin in these HN4 cells, we were interested in
whether ß-catenin showed altered expression. Immunofluorescence confirmed the
expression of ß-catenin in the HN4 vimentin mutants, as seen in Fig. 15. All of the cell
lines express ß-catenin, and there appears to be little difference in the staining between the
various mutants either in terms of intensity or localization.
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Figure 15: ß-catenin expression in HN4 vimentin-transfected cells. Cells were cultured
on glass coverslips and fixed as described in ‘Methods.’ Cells were incubated with anti- ßcatenin antibody overnight, and then incubated with a FITC-conjugated anti- goat antibody
for 1h and counterstained with DAPI.
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Effect of Vimentin Overexpression in HN4 Cells on the Presence of E-cadherin
E-cadherin is a major molecule in the adherens junction, and it plays are large role
in EMT due to its interaction with ß-catenin (Voulgari & Pintzas, 2009). In tumorigenesis,
E-cadherin is commonly inactivated or silenced by various mechanisms. We used
immunofluorescence to determine whether the presence of vimentin in HN4 cells affects or
alters the expression of E-cadherin. Our results show distribution of E-cadherin is altered
in cells expressing wild-type or mutant forms of vimentin. As seen in Fig. 16, cells
encoding the wild-type version of vimentin show E-cadherin staining resembling the
HN4V control cells. However, there are distinct changes in the other two vimentin
expressing mutants. In cells encoding the PKCe-phosphomimetic version of vimentin, the
E-cadherin is present in packets throughout the cytoplasm. Cells encoding the
unphosphorylatable version of vimentin show a variety of different E-cadherin patterns,
and the entire sample consisted of the variations shown in Fig. 16. Clearly, the expression
of E-cadherin is altered in cells encoding the unphosphorylatable version of vimentin.
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Figure 16: E-cadherin expression in HN4 vimentin-transfected cells. Cells were
cultured on glass coverslips and fixed as described in ‘Methods.’ Cells were incubated
with anti- E-cadherin antibody overnight, and then incubated with a FITC-conjugated antirat antibody for 1h and counterstained with DAPI.
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NF-?B Inhibitor Effects Vimentin-Positive HN12 Cells
Previous research in our lab showed an increase in K13, K14, and K15 expression
in vimentin knock-down cells. Additionally, studies have shown that NF-?B transcription
factors may be involved in keratin repression (Blumenberg, 2006). Also, NF-?B is
commonly involved in tumor progression. To examine the effect of NF-?B on vimentin
and keratin expression, we used an NF-?B inhibitor on vimentin-positive HN12 cells.
Initially, we performed an MTT assay to determine the appropriate concentration of NF-?B
inhibitor to use without being toxic to the cells. Cells were counted, plated in triplicate, and
allowed to grow for 7 days. After 7 days, the MTT assay was performed, and the
absorbance was measured by spectrophotometer. Fig. 17 shows the results of different NF?B inhibitor concentrations on HN12 cells. The presence of the NF-?B inhibitor resulted in
decreased HN12 cell growth. This decrease in cell growth is greater with an increasing
concentration of the NF-?B inhibitor. In initial studies, we used 200nM. First, we
performed a qRT-PCR on the cDNA template using vimentin-specific primers. Fig. 18
shows vimentin expression was decreased in the vimentin-positive HN12 cells after being
treated with 200nM NF-?B inhibitor. After we observed a decrease in vimentin expression,
we determined the effect of the NF-?B inhibitor on cell proliferation. Cells were plated in
triplicate and counted over 8 days. Fig. 19 shows that the presence of 200nM NF-?B
inhibitor also resulted in decreased proliferation of vimentin-positive HN12 cells.
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Figure 17: Dose-response of HN12 cells with NF-?B inhibitor. Cells (5 x 103 per well)
were plated in triplicate in 12-well plates and incubated as described in ‘Methods.’ After 7
days, the MTT assay was performed.
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Figure 18: NF-?B inhibition leads to reduced vimentin expression in HN12 cells. Total
RNA was extracted and reverse-transcribed to create cDNA, and then qRT-PCR was
performed as described in ‘Methods.’ The relative expression ratio represents expression of
vimentin to the internal standard actin.
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Figure 19: NF-?B inhibition leads to reduced proliferation of HN12 cells. Cells (5 x
103 per well) were plated in triplicate in 6-well plates and incubated as described in
‘Methods.’ Cell counting began 4 days after cells were plated, and they were counted
everyday until day 8.
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5-Aza-dC Affects Vimentin-Positive HN12 Cells
Previous research in our lab suggested that the promoter of DKK3, a Wnt
antagonist, is methylated in advanced HNSCC cells. This methylation represses DKK3
expression in these cells. HN12 cells grown in the presence of 5-Aza-dC removes this
repression and transcriptional targets of ß-catenin are decreased. ß-catenin has also been
shown to enhance vimentin expression. Therefore, it is possible that repressing DKK3
could enhance Wnt signaling and lead to increased vimentin expression, which might
additionally cause decreased keratin expression. To explore the effect of 5-Aza-dC on cell
growth in vimentin-positive HN12, we performed an MTT assay. Cells were counted,
plated in triplicate, and allowed to grow for 7 days. After 7 days, the MTT assay was
performed, and the absorbance was measured by a spectrophotometer the next day. Fig. 20
shows the result of the MTT assay. HN12 cells grown in the presence of 5-Aza-dC resulted
in decreased cell growth. After seeing a decrease in cell growth by the MTT assay, we
performed a cell proliferation assay on HN12 cells grown in the presence of 5-Aza-dC. In
Fig. 21, the effect of 5-Aza-dC on HN12 cell proliferation is shown. When grown in the
presence of 5-Aza-dC, HN12 cells have decreased proliferation.
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Figure 20: 5-Aza-dC leads to reduced cell growth in HN12 cells. Cells (5 x 103 per
well) were plated in triplicate in 12-well plates and incubated as described in ‘Methods.’
After 7 days, the MTT assay was performed.
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Figure 21: 5-Aza-dC leads to reduced proliferation of HN12 cells. Cells (5 x 103 per
well) were plated in triplicate in 6-well plates and incubated as described in ‘Methods.’
Cell counting began 4 days after cells were plated, and they were counted everyday until
day 8.
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Combined Effect of NF-?B Inhibitor and 5-Aza-dC on Vimentin-Positive HN12 Cells
In addition to NF-?B repressing keratin expression and methylation of DKK3
allowing Wnt signaling in HN12 cells, there is also a possibility that Wnt signaling could
activate NF-?B or that these pathways might act in concert. After observing the individual
effects of the NF-?B inhibitor and 5-Aza-dC on HN12 cells, we grew the cells under both
conditions to see if there is a combined effect. For these experiments, we used 2µM NF-?B
inhibitor. As shown in Fig. 17, this concentration provided a greater decrease in cell
growth than 200 nM, but did not appear toxic to the cells. Initially, we performed a MTT
assay, and Fig. 22 shows the effect of the NF-?B inhibitor, 5-Aza-dC, and the combined
effect of both on HN12 cells. The growth of HN12 cells was decreased in all three
conditions. However, the greatest decrease in growth was seen with the NF-?B inhibitor
and the combination of the NF-?B inhibitor and 5-Aza-dC. After seeing a significant
decrease at day 7, we decided to perform an MTT assay on days 5, 6, and 7 to determine if
it was a gradual change. Fig. 23 shows the difference between the results on each of these
three days. The greatest increase in growth appears between days 6 and 7. To explore this
further, we performed a cell proliferation assay. Cells were plated in triplicate and counted
over 8 days. Fig. 24 shows the results of the cell proliferation assay. Clearly, HN12 cells
proliferate at a slower rate when grown in the presence of the NF-?B inhibitor or 5-AzadC. A greater decrease was seen again with either 2µM NF-?B inhibitor or the
combination of the NF-?B inhibitor and 5-Aza-dC. Additionally, we decided to investigate
vimentin expression in HN12 cells treated with these conditions using western blotting and
immunofluorescence. Fig. 25 shows that vimentin was expressed in the cells treated with
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the NF-?B inhibitor, 5-Aza-dC, or a combination of the two. However, vimentin
expression was decreased in all of the treated cell lines, and the largest decrease was seen
in the cells treated with 5-Aza-dC. The results of our immunostaining experiment are
shown in Fig. 26. Again, vimentin expression is present in the cell lines treated with NF?B inhibitor or 5-Aza-dC, but the expression is much weaker in the treated cells than the
control HN12 cells.
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Figure 22: NF-?B inhibitor and 5-Aza-dC reduce HN12 cell growth. Cells (5 x 103 per
well) were plated in triplicate in 12-well plates and incubated as described in ‘Methods.’
After 7 days, the MTT assay was performed.
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Figure 23: Growth change as a result of NF-?B inhibitor or 5-Aza-dC is gradual.
Cells (5 x 103 per well) were plated in triplicate in 12-well plates and incubated as
described in ‘Methods.’ Three 12-well plates were plated for each set of conditions. On
day 5, 6, and 7, the MTT assay was performed.
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Figure 24: NF-?B inhibitor and 5-Aza-dC reduce HN12 cell proliferation. Cells (5 x
103 per well) were plated in triplicate in 6-well plates and incubated as described in
‘Methods.’ Cell counting began 4 days after cells were plated, and they were counted daily
until day 8.
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Figure 25: Vimentin expression is decreased in HN12 cells treated with NF-?B
inhibitor or 5-Aza-dC. Total protein extracts were prepared as described in ‘Methods’
and analyzed for vimentin expression (top panel). Levels of actin were determined as a
loading control (lower panel).
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Figure 26: Vimentin expression in HN12 cells treated with NF-?B inhibitor or 5-AzadC using immunofluorescence. Cells were cultured on glass coverslips and fixed as
described in ‘Methods.’ Cells were incubated with anti- vimentin antibody overnight, and
then incubated with a FITC-conjugated anti- mouse antibody for 1h and counterstained
with DAPI.
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Effects of DKK3 shRNA Expression in Vimentin- negative HN4 Cells
Research in our laboratory suggests that DKK3, a Wnt antagonist, is repressed by
methylation in HN12 cells. To confirm the difference of DKK3 expression in vimentinnegative HN4 cells and vimentin-positive HN12 cells, a qRT-PCR analysis was performed
using DKK3-specific primers. Fig. 27 confirms there is a difference in DKK3 expression
between these two cell lines, and the amount of DKK3 expressed in HN12 cells is
significantly decreased compared to HN4 cells. HN4 cells that express DKK3 shRNA were
previously generated in our laboratory, and we performed a qRT-PCR with DKK3-specific
primers to confirm the quantity of the DKK3 inhibition. Based on the results in Fig. 28, the
shDKK3 clones 1 and 4 were used for further study. After confirming the inhibition of
DKK3 in these clones by qPCR, a western blot analysis was performed. As seen in Fig.
29, cell lysates from the HN4 cells had the largest amount of DKK3 expression. A
decrease in DKK3 expression was seen in the HN12 cell lysates, but a much clearer
decrease was shown by the HN4 shDKK3 #1 cell lysates. This western blot also illustrated
that HN4 shDKK3 #4 was not a substantial DKK3 knockdown. We also detected vimentin
expression in the HN4 shDKK3 #1 cell lysates. Vimentin expression was seen in the HN12
cells as well. Additionally, conditioned media from HN4 and HN4 shDKK3 cells were
immunoprecipitated with a DKK3 antibody to determine DKK3 secretion from these cells.
HN4, HN4 shDKK3 #1, and HN4 shDKK3 #4 cells were counted and plated in normal
growth medium. After 24 h, cells were washed with PBS and placed in serum- free
medium. The conditioned medium was collected from the cells, and immunoprecipitation
was performed using a DKK3 antibody. Fig. 30 shows the expression of DKK3 from these
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three immunoprecipitation reactions. All three samples from the immunoprecipitation
reactions showed expression of DKK3, although the expression in the HN4 shDKK3 cells
was slightly decreased compared to the amount of DKK3 secreted by the HN4 control
cells.
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Figure 27: Expression of DKK3 in HN12 and HN4 cells. Total RNA was extracted and
reverse-transcribed to create cDNA, and then qRT-PCR was performed as described in
‘Methods.’ The relative expression ratio represents the expression of DKK3 to the internal
standard, actin.
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Figure 28: shRNA-mediated inhibition of DKK3. Total RNA was extracted and
reverse-transcribed to create cDNA, and then qRT-PCR was performed as described in
‘Methods.’ The relative expression ratio represents the expression of DKK3 to the internal
standard, actin.
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Figure 29: DKK3 and vimentin expression in HN4 cells expressing DKK3 shRNA.
Total cell protein extracts were prepared as described in ‘Methods’ and analyzed for
DKK3 expression (top panel) or vimentin (middle panel). Levels of actin were determined
as a loading control (lower panel).

79

Figure 30: DKK3 is secreted by HNSCC cells. Cells were counted and plated in normal
growth medium. After 24 h, cells were washed with PBS and placed in serum- free
medium. The conditioned medium was collected from the cells, and the
immunoprecipitation reaction was performed as described in ‘Methods’ using the DKK3
antibody.
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Discussion
Aims of Current Study
The aims of this study were to determine keratin gene expressio n and biological
response in cells that express wild-type and PKC phosphorylation site mutants of vimentin
and to determine the role of Wnt signaling in vimentin expression during EMT.

Overexpression of Vimentin in Vimentin- negative HN4 Cells
EMT is the process that is responsible for allowing epithelial tumors to metastasize
to other tissues (Stadler et al., 2008). Undergoing EMT usually results in decreased cell
anchorage and increased cell motility. Vimentin expression is associated with EMT and
increased metastatic potential (Ghosh et al., 2002). EMT is also characterized by a
decrease in epithelial cell markers, such as E-cadherin (Lester et al., 2007). Previous
research in our lab showed that when vimentin expression is inhibited in HN12 cells by
shRNA, the cells exhibited decreased proliferation and motility, as well as re-expression of
keratins (Paccione et al., 2008).
To determine the effect on keratin gene expression in response to vimentin
overexpression, plasmids encoding wild-type vimentin, a PKCe-phosphomimetic
(aspartate mutant) version of vimentin, or an unphosphorylatable (alanine mutant) version
of vimentin were expressed in vimentin- negative HN4 cells. Vimentin overexpression was
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confirmed by western blot analysis, and the clone with the strongest overexpression was
used for further experiments. The presence of wild-type vimentin has been shown to
enhance cell motility in a PKCe-dependent manner. When these sites are substituted with
alanine, vimentin can no longer induce cell motility, while aspartate substitutions allow
motility in PKCe null cells. These PKC-mediated phosphorylation sites on vimentin are
very important in integrin trafficking through the cell (Ivaska et al., 2005), and the ability
of vimentin to assemble into polymers is largely regulated by phosphorylation (Inagaki,
Inagaki, Takahashi, & Takai, 1997). Additionally, the expression of vimentin is associated
with increased migration of cells involved in EMT (Kang & Massague, 2004). We
examined the level of keratin 14 in cells that co-express vimentin. Our western blot
analysis shows that the overexpression of vimentin in HN4 cells has an effect on the
expression of keratin 14 protein. The amount of keratin 14 appears to be decreased in the
cells expressing the wild-type version of vimentin or the PKCe-phosphomimetic version of
vimentin when compared to the control HN4V cells. The cells with the unphosphorylatable
version of vimentin have an increased level of keratin 14 protein compared to the control
HN4V cells. These results suggest that the overexpression of vimentin is having an effect
on the expression of keratin 14 in HN4 cells. Additionally, the phosphorylation status of
vimentin likely plays a role in this differential keratin 14 expression. However, the results
of our qRT-PCR experiments suggest that the expression of the unphosphorylatable
version of vimentin in HN4 cells leads to a substantial reduction in the level of keratin 14
mRNA. There is less transcription of keratin 14 in the cells encoding the
unphosphorylatable version of vimentin, but the protein may be more stable leading to
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enhanced levels of protein seen in the western blot and immunofluorescence experiments.
This may be a consequence of the differential vimentin phosphorylation and suggests that
the unphosphorylatable version of vimentin may stabilize the protein directly or indirectly.
As mentioned above, Ivaska and co-workers found that PKCe-mediated phosphorylation of
vimentin controls endocytic vesicle association with intermediate filaments, which is
responsible for recycling endocytosed integrins to the plasma membrane, and the
substitution of alanine at the PKC-regulated N-terminal phosphorylation sites removes the
capability of vimentin to initiate cell motility in PKCe-expressing cells (Ivaska et al.,
2005). Once an effect was seen on keratin 14 expression by western blotting and qRTPCR, we decided to look at the presence of vimentin and keratin 14 by
immunofluorescence. Vimentin staining was not present in the control HN4 vector
transfected cells, but the staining was clear in the cells encoding the wild-type, PKCephosphomimetic, or unphosphorylatable versions of vimentin. Vimentin staining in HN12
shows distinct filaments. However, the staining seen in the mutants differs from this
filamentous appearance. The cells encoding the unphosphorylatable version of vimentin
has the most distinct staining. Instead of a filament structure, these cells show vimentin in
small packets. The cells encoding the PKCe-phosphomimetic version of vimentin has
staining that closely resembles HN12. However, the vimentin appears as “squiggles”
instead of long filaments. These “squiggles” are thought to be precursors to the longer
intermediate filaments that are seen in fibroblasts. The changes in filament structure seen
by Ghosh et al. were the result of changes in integrin expression that affected ERK
activation (Ghosh et al., 2002). This suggests that mutations at the PKCe-phosphorylation
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sites cause defects in intermediate filament assembly. The differences in the appearance of
vimentin may be a result of the phosphorylation site substitutions. We also found that all
three mutant cell lines clearly expressed keratin 14. The keratin 14 expression in the cells
encoding wild-type vimentin or the PKCe-phosphomimetic version of vimentin resembled
the staining in the HN4V cells. The cells encoding the unphosphorylatable version of
vimentin displayed a different pattern of keratin 14 staining. As seen with vimentin, these
cells express keratin 14 in small packets as opposed to filaments. This further suggests that
these mutated phosphorylation sites play a role in intermediate filament structure and/or
assembly and/or trafficking.

Overexpression of Vimentin is Important in HN4 Biological Properties
In order to determine whether the overexpression of vimentin affects the phenotype
of HN4 cells, we assessed the growth of HN4 vimentin transfectants using MTT assays
and cell counting. The cells with the wild-type or PKCe-phosphomimetic versions of
vimentin showed a significant increase in growth when compared to the HN4V cells.
Additionally, the cells with the unphosphorylatable version of vimentin showed a growth
level very similar to the HN4V cells. These results suggest that vimentin phosphorylation
might contribute positively to cell growth. A wound-closure (scratch) assay was performed
on these cells as well, to test if the expression of vimentin altered or affected cell motility.
We found that cells expressing the wild-type or PKCe-phosphomimetic versions of
vimentin migrated at a faster rate than the HN4V cells and the cells with the
unphosphorylatable version of vimentin. Thus, in addition to effects on proliferation, the
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ability to phosphoryla te vimentin plays a part in cell motility. Other studies have shown
that blocking vimentin in breast, head and neck, or colon cancer cells has significantly
affected motility and migration. Integrins are important in communication between the
cells and the extracellular matrix, and the pattern of integrins is frequently altered during
tumor progression (Zhang et al., 2009). For example, squamous carcinoma cells that have
increased proliferation frequently express higher levels of a 6 ß 4. When a 6 ß4 integrin binds to
an extracellular ligand, it is phosphorylated on tyrosine residues and combines with the
adaptor proteins Shc and Grb2. This leads to activation of Ras, which causes activation of
both Ras- Erk and Rac-Jnk signaling pathways. These pathways mediate immediate-early
gene transcription and cell cycle progression (Mainiero et al., 1997). Additionally, Ras is
capable of signaling through PI3K and Rho GTPases, which can work together with
transforming growth factor-ß to induce EMT (Guarino, 2007). Based on studies by Ivaska
et al. (2005), altered phosphorylation of vimentin may influence integrin signaling and,
thus, impact growth and motility.

Effect of Vimentin Expression on E-cadherin in HN4 Cells
E-cadherin is a calcium-binding transmembrane glycoprotein. The extracellular
domain interacts with adjacent cell receptors, and the intracellular domain interacts with
catenins. E-cadherin is the major molecule in the adherens junction, and it plays an
important role in EMT because of its interaction with ß-catenin (Voulgari & Pintzas,
2009). ß-catenin interacts directly with the cytoplasmic N-terminal domain of E-cadherin
(Ziober et al., 2001). In tumorigenesis, E-cadherin is frequently inactivated or silenced by

85
various mechanisms., including repression by transcription factors ZEB1 and ZEB2
(Korpal, Lee, Hu, & Kang, 2008).
We decided to investigate the presence of E-cadherin in the HN4 cells with
vimentin overexpression. E-cadherin was present in all four cells lines, but the appearance
of E-cadherin was varied. The E-cadherin staining in the cells encoding the wild-type
version of vimentin was most similar to the HN4V cells. The cells with the PKCephosphomimetic version of vimentin showed E-cadherin in the cytoplasm, but it was also
contained in isolated packets. These packets were consistent amongst the entire sample.
The E-cadherin staining in the cells containing the unphosphorylatable version of vimentin
was very diverse. Some of these cells displayed E-cadherin in packets as seen in the cells
with the PKCe-phosphomimetic version of vimentin. Another observation in these cells
was slight polarization of the E-cadherin. Again, this polarization was only seen in the
altered E-cadherin. Others showed the E-cadherin in large packets. The E-cadherin
expression was clearly disrupted.
One study of HNSCC cells showed that activation of Src, a protein tyrosine kinase,
was correlated with decreased expression of E-cadherin and the detection of vimentin. The
expression of E-cadherin in well-differentiated tumors was found with weak p-Src
expression and a lack of vimentin expression. However, high levels of activated Src and
the presence of vimentin were found in poorly-differentiated tumors, along with a lack of
E-cadherin expression. This study also demonstrated that E-cadherin was expressed in the
membrane and cytoplasm in some carcinomas, which indicates qualitative and quantitative
changes in tumor cell expression of E-cadherin (Mandal et al., 2008). It is possible that E-
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cadherin is present, but the junctional complex is defective, which allows for the cells to be
more invasive (Ziober et al., 2001). Other studies have shown that while expression of Ecadherin remained relatively constant in oral squamous cell carcinoma cells, the expression
of intermediate filaments and integrins did change (Ghosh et al., 2002).

Inhibition of NF-?B Affects Growth in HN12 Cells
Abnormal expression of NF-?B has been described in many cancers, including
head and neck, prostate, lung and pancreatic adenocarcinomas and can enhance survival
(Min, Eddy, Sherr, & Sonenshein, 2008). Inhibition of NF-?B resulted in decreased
proliferation of HN12 cells. It also caused a decrease in vimentin mRNA expression.
Reduced proliferation could be a result of the decrease in vimentin expression. However, it
is also possible that the decreased proliferation caused by the NF-?B inhibitor is caused by
the lack of transcription of other genes regulated by NF-?B. NF-?B regulates genes
encoding proteins involved in cell growth, such as cyclin D1 (Min et al., 2008). Cyclin D1
is an important regulator of cell proliferation, and it is commonly up-regulated in
tumorigenesis (Witzel, Koh, & Perkins, 2010).
NF-?B transcription factors play an important role in head and neck cancers, and
they are commonly overexpressed in these cancers. 85% of HNSCC patients have shown
increased nuclear localization of NF-?B (Stadler et al., 2008). Active NF-?B is found in
the nucleus, and it can be inhibited by I?B keeping it contained in the cytoplasm. The
transcription of several genes is regulated by NF-?B, including cytokines, growth factors,
cell adhesion molecules, and pro-/antiapoptotic proteins (Lee et al., 2007). Studies have
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also shown that NF-?B transcription factors are able to repress keratin expression
(Blumenberg, 2006). Since these NF-?B transcription factors are frequently present in
metastatic cells, we were interested in determining the effect of an NF-?B inhibitor on
HN12 cells. Other studies have shown inhibition of NF-?B resulting in inhibited tumor cell
survival, proliferation, migration, angiogenesis, and tumorigenesis in squamous cell
carcinoma (Loercher et al., 2004).

5-Aza-dC Affects Growth of HN12 Cells
The Wnt signaling pathway is able to promote tumor growth by altering cell
proliferation and differentiation. DKK3 is a Wnt antagonist, and when Wnt signaling is
inhibited, ß-catenin is phosphorylated and targeted for degradation. The catenins are
responsible for transduction of extracellular contacts between cadherins during epithelial
reorganization. ß-catenin is able to translocate to the nucleus where it affects gene
transcription, and recent studies have shown that it can also act as an oncogene. There are
reports of high ß-catenin expression in both colon carcinoma cells and melanoma cells
(Ziober et al., 2001). ß-catenin staining in normal fibroblasts and endothelial cells is
restricted to the cytoplasm and/or cell membranes. In normal epithelial cells, it is found
only in the cell membrane, and it is predominantly located in the nucleus of mesenchymal
cells (Voulgari & Pintzas, 2009). ß-catenin accumulation in the cytoplasm and
translocation to the nucleus is associated with epithelial cell migration and processes
involved in EMT (Gilles et al., 2003). Studies have shown that DKK3 is expressed in
normal adult tissues, but the DKK3 gene is repressed in several human cancer cell lines
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(Yu et al., 2009). Previous research in our lab showed reduced expression of DKK3 in
HN12 cells (Miyazaki et al., 2006). Thus, we wanted to investigate the effect of 5-Aza-dC
on HN12 cells to determine if cell growth was altered by the presence of this
demethylating agent. The presence of 5-Aza-dC should remove the methylation repression
on DKK3 and allow DKK3 to inhibit Wnt signaling in these cells. Our results show a
decrease in cell growth as a result of treatment with 5-Aza-dC. The re-expression of DKK3
to inhibit Wnt signaling and prevent ß-catenin translocation to the nucleus in these HN12
cells may have contributed to this decrease in cell growth.
Some cancers exhibit decreased DKK3 expression due to hypermethylation of the
promoter (Kobayashi et al., 2002). DKK3 expression is commonly repressed in gastric and
colorectal cancers due to promoter methylation, and this is correlated with poor patient
prognosis. When heavily methylated and silenced cell lines from colon and gastric cancer
were treated with 5-Aza-dC, a demethylating agent that inhibits DNA- methyltransferase
activity, and trichostatin A (histone deacetylase inhibitor), the expression of DKK3 was
restored. This implies that CpG methylation was responsible for DKK3 repression in these
cells. DKK3 expression has caused growth inhibition in lung cancer cells, osteosarcoma
cells, and digestive cancer cells, which suggests DKK3 may function as a tumor suppressor
(Yu et al., 2009).
After observing a decrease in growth of HN12 cells in the presence of NF-?B
inhibitor or 5-Aza-dC, we wanted to determine the combined effect on HN12 cells. Cell
growth was decreased in cells grown in the presence of both NF-?B inhibitor and 5-AzadC. However, no additive effect was apparent. Instead, the decrease seen with both
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treatments resembled the treatment with the NF-?B inhibitor alone. This suggests that they
may target the same pathway. This is consistent with previous studies, which show that in
Wnt signaling when GSK-3ß is inhibited, the NF-?B inhibitor, I?Ba, is targeted by
ubiquitin for destruction (Bachelder, Yoon, Franci, de Herreros, & Mercurio, 2005). This
suggests that Wnt signaling could activate NF-?B. However, further study could be done
using a smaller concentration of the NF-?B inhibitor. This would eliminate the possibility
of maximum inhibition being achieved by NF-?B inhibitor alone.
Additionally, we investigated vimentin expression in HN12 cells treated with the
NF-?B inhibitor, 5-Aza-dC, or a combined treatment. Our western blot showed decreased
vimentin expression in HN12 cells treated with all three conditions. Treatment with 5-AzadC showed the largest decrease in vimentin expression, but the decrease seen with
treatment of the NF-?B inhibitor or the NF-?B inhibitor combined with 5-Aza-dC was very
similar. We also observed a change in vimentin expression using immunofluorescence.
The control HN12 cells showed vimentin filaments throughout the cytoplasm. However,
this filament structure was altered in HN12 cells treated with NF-?B inhibitor or 5-AzadC. First, vimentin expression was decreased under all three conditions. Secondly,
vimentin was not expressed in long filaments. Instead, the staining showed short squiggles,
which suggests that vimentin filament assembly was disrupted. These findings are
consistent with our hypothesis that Wnt signaling plays a role in vimentin expression
during EMT. When the Wnt signaling pathway is inhibited, by removing promoter
methylation on DKK3 with 5-Aza-dC treatment, the level of vimentin expression is
decreased.
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DKK3 Knockdown in Vimentin- negative HN4 Cells
HN4 cells were previously generated in our lab that express DKK3 shRNA. The
clones displaying the largest inhibition of DKK3 were chosen for further study. We
performed a western blot to confirm the DKK3 knockdown, and we also determined
vimentin expression in these cell lines. Our results showed vimentin expression in HN12
and HN4 shDKK3 #1 cells. This supports our hypothesis that Wnt signaling plays a role in
vimentin expression. By inhibiting DKK3, Wnt signaling was activated in these HN4
shDKK3 #1 cells and vimentin was expressed. The presence of vimentin was not detected
in the HN4 cells. Vimentin expression was not present in the HN4 shDKK3 #4 cells either,
which is not surprising since our western blot showed this was not a strong DKK3
knockdown. Since DKK3 is a secreted glycoprotein, conditioned medium was collected
from HN4 and HN4 shDKK3 cells and immunoprecipitated with a DKK3 antibody to
determine DKK3 secretion from these cells. Studies done in human islet cells have shown
that DKK3 expression in pancreatic B cells is characteristic of a secreted protein (Welters
& Kulkarni, 2008). Our immunoprecipitation showed secretion of DKK3 in the HN4 and
HN4 shDKK3 medium. Although the expression was low, the level seen in the HN4
shDKK3 conditioned medium was reduced compared to the HN4 cells. Further study will
need to examine the effect of DKK3 repression on keratin 14 expression.
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Future Studies
In this study, we have shown that overexpression of vimentin in vimentin- negative
HN4 cells causes changes in cell growth, motility, and keratin 14 expression. These
changes may be due to altered vimentin phosphorylation. To determine that PKC
phosphorylation of vimentin is responsible for these biological changes, these vimentin
overexpressing cells could be treated with a PKC inhibitor, such as bisindolylmaleimide I
(BIM-I). Studying proliferation and migration in cells treated with BIM-I would allow us
to determine if the effects of vimentin overexpression can be overridden. However, to
determine whether vimentin is causing keratin 14 changes at the gene expression level, we
could perform a promoter deletion assay. This would allow us to determine the regions of
the keratin promoter necessary for transcriptional repression. We could also perform a
chromatin immunoprecipitation (ChIP) assay to determine whether specific transcription
factors are bound to the keratin promoter. Additionally, we could investigate whether the
overexpression of vimentin and inhibition of keratin have a combined effect on EMT. For
example, keratin expression could be repressed using shRNA.
Immunofluorescence showed altered E-cadherin expression in the HN4 cells with
vimentin overexpression. This suggests that mutations in these vimentin phosphorylation
sites can affect junctional proteins. Further investigation of E-cadherin by western blot and
qRT-PCR would determine whether expression is increased or decreased in these cells.
Additionally, the levels of E-cadherin should be assessed when these cells are treated with
BIM-I.
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Our study also revealed HN12 cells grown in the presence of a NF-?B inhibitor or
5-Aza-dC showed decreased growth. We are interested in determining whether the result
seen with the combined presence of the NF-?B inhibitor and 5-Aza-dC is due to the high
concentration of NF-?B inhibitor. To investigate this, we will use a lower concentration of
the NF-?B inhibitor, since it showed a similar effect on growth when compared to 5-AzadC. If the two treatments are synergistic, there should be a decreased level of growth that is
smaller than what is observed with the individual treatments of the NF-?B inhibitor or 5Aza-dC.
Additionally, we should investigate the effects of NF-?B inhibitor and 5-Aza-dC
treatments on vimentin and keratin 14 expression in HN12 cells. This can be explored
using a variety of techniques, such as western blotting, qRT-PCR, and
immunofluorescence. We would predict that 5-Aza-dC would remove the methylation
repression on the Wnt antagonist DKK3 and block Wnt signaling in these HN12 cells.
Since this would be expected to cause degradation of ß-catenin, we should compare the
level of ß-catenin in HN12 cells and HN12 cells treated with 5-Aza-dC. We could assess
the presence of ß-catenin by western blotting and immunofluorescence. Repression of ßcatenin in these HN12 cells should result in a decrease of vimentin expression and an
increase of keratin 14 expression.
Furthermore, inhibiting DKK3 expression in HN4 cells should activate Wnt
signaling in these vimentin-negative cells. We would like to explore the effect of repressed
DKK3 expression on vimentin, keratin 14, and ß-catenin expression in HN4 cells. These
experiments would allow us to further determine the role of Wnt signaling in EMT.
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